Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Stephen M. Ansell, MD, PhD
Published: Thursday, Jun 22, 2017



Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.
SELECTED
LANGUAGE


Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x